Multimarker risk stratification approach at multiple sclerosis onset

Multimarker risk stratification approach at multiple sclerosis onset

Copyright © 2017 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 181(2017) vom: 01. Aug., Seite 43-50
1. Verfasser: Fernández-Paredes, Lidia (VerfasserIn)
Weitere Verfasser: Casrouge, Armanda, Decalf, Jérémie, de Andrés, Clara, Villar, Luisa Maria, Pérez de Diego, Rebeca, Alonso, Bárbara, Álvarez Cermeño, José Carlos, Arroyo, Rafael, Tejera-Alhambra, Marta, Navarro, Joaquín, Oreja-Guevara, Celia, López Trascasa, Margarita, Seyfferth, Ansgar, García Martínez, Maria Angel, Álvarez Lafuente, Roberto, Albert, Matthew L, Sánchez-Ramón, Silvia
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Biomarkers Diagnostic Innate immunity deregulation Prognostic CCL11 protein, human CCL2 protein, human CCL4 protein, human CCL5 protein, human mehr... CXCL10 protein, human CXCL9 protein, human Chemokine CCL11 Chemokine CCL2 Chemokine CCL4 Chemokine CCL5 Chemokine CXCL10 Chemokine CXCL9 HGF protein, human IL1RN protein, human IL7 protein, human Interleukin 1 Receptor Antagonist Protein Interleukin-7 Fibroblast Growth Factor 2 103107-01-3 Epidermal Growth Factor 62229-50-9 Hepatocyte Growth Factor 67256-21-7 DPP4 protein, human EC 3.4.14.5 Dipeptidyl Peptidase 4
LEADER 01000naa a22002652 4500
001 NLM272583812
003 DE-627
005 20231224235159.0
007 cr uuu---uuuuu
008 231224s2017 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2017.05.019  |2 doi 
028 5 2 |a pubmed24n0908.xml 
035 |a (DE-627)NLM272583812 
035 |a (NLM)28578025 
035 |a (PII)S1521-6616(16)30700-8 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Fernández-Paredes, Lidia  |e verfasserin  |4 aut 
245 1 0 |a Multimarker risk stratification approach at multiple sclerosis onset 
264 1 |c 2017 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 28.08.2017 
500 |a Date Revised 06.02.2018 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2017 Elsevier Inc. All rights reserved. 
520 |a Delay in the diagnosis of multiple sclerosis (MS) stems from the lack of specific clinical and analytical markers to assist in the early diagnosis and prediction of progressive course. We propose a decision-tree model that better defines early at onset MS patients and those with the progressive form by analysing a 12-biomarkers panel in serum and CSF samples of patients with MS, other neurological diseases (OND) and healthy contols. Thus, patients at onset of neurological disease were first classified by serum IL-7 levels <141pg/ml (OR=6.51, p<0.001). Combination of IL-7 and CXCL10 indicated risk for a specific MS clinical form, where IL-7<141 and CXCL10<570pg/ml were associated with the highest risk for PP-MS (OR=22, p=0.01). Unexpectedly, both PP-MS and RR-MS patients shared significantly decreased prototypical biomarkers of inflammation and tissue regeneration in CSF than OND suggesting a defective intrinsic immune response playing a role at the beginning of the disease 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Biomarkers 
650 4 |a Diagnostic 
650 4 |a Innate immunity deregulation 
650 4 |a Prognostic 
650 7 |a Biomarkers  |2 NLM 
650 7 |a CCL11 protein, human  |2 NLM 
650 7 |a CCL2 protein, human  |2 NLM 
650 7 |a CCL4 protein, human  |2 NLM 
650 7 |a CCL5 protein, human  |2 NLM 
650 7 |a CXCL10 protein, human  |2 NLM 
650 7 |a CXCL9 protein, human  |2 NLM 
650 7 |a Chemokine CCL11  |2 NLM 
650 7 |a Chemokine CCL2  |2 NLM 
650 7 |a Chemokine CCL4  |2 NLM 
650 7 |a Chemokine CCL5  |2 NLM 
650 7 |a Chemokine CXCL10  |2 NLM 
650 7 |a Chemokine CXCL9  |2 NLM 
650 7 |a HGF protein, human  |2 NLM 
650 7 |a IL1RN protein, human  |2 NLM 
650 7 |a IL7 protein, human  |2 NLM 
650 7 |a Interleukin 1 Receptor Antagonist Protein  |2 NLM 
650 7 |a Interleukin-7  |2 NLM 
650 7 |a Fibroblast Growth Factor 2  |2 NLM 
650 7 |a 103107-01-3  |2 NLM 
650 7 |a Epidermal Growth Factor  |2 NLM 
650 7 |a 62229-50-9  |2 NLM 
650 7 |a Hepatocyte Growth Factor  |2 NLM 
650 7 |a 67256-21-7  |2 NLM 
650 7 |a DPP4 protein, human  |2 NLM 
650 7 |a EC 3.4.14.5  |2 NLM 
650 7 |a Dipeptidyl Peptidase 4  |2 NLM 
650 7 |a EC 3.4.14.5  |2 NLM 
700 1 |a Casrouge, Armanda  |e verfasserin  |4 aut 
700 1 |a Decalf, Jérémie  |e verfasserin  |4 aut 
700 1 |a de Andrés, Clara  |e verfasserin  |4 aut 
700 1 |a Villar, Luisa Maria  |e verfasserin  |4 aut 
700 1 |a Pérez de Diego, Rebeca  |e verfasserin  |4 aut 
700 1 |a Alonso, Bárbara  |e verfasserin  |4 aut 
700 1 |a Álvarez Cermeño, José Carlos  |e verfasserin  |4 aut 
700 1 |a Arroyo, Rafael  |e verfasserin  |4 aut 
700 1 |a Tejera-Alhambra, Marta  |e verfasserin  |4 aut 
700 1 |a Navarro, Joaquín  |e verfasserin  |4 aut 
700 1 |a Oreja-Guevara, Celia  |e verfasserin  |4 aut 
700 1 |a López Trascasa, Margarita  |e verfasserin  |4 aut 
700 1 |a Seyfferth, Ansgar  |e verfasserin  |4 aut 
700 1 |a García Martínez, Maria Angel  |e verfasserin  |4 aut 
700 1 |a Álvarez Lafuente, Roberto  |e verfasserin  |4 aut 
700 1 |a Albert, Matthew L  |e verfasserin  |4 aut 
700 1 |a Sánchez-Ramón, Silvia  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 181(2017) vom: 01. Aug., Seite 43-50  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:181  |g year:2017  |g day:01  |g month:08  |g pages:43-50 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2017.05.019  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 181  |j 2017  |b 01  |c 08  |h 43-50